Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2012 Sep;11(3):363-9.
doi: 10.1007/s10689-012-9521-y.

Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance

Collaborators, Affiliations
Practice Guideline

Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance

Irma Kluijt et al. Fam Cancer. 2012 Sep.

Abstract

Hereditary diffuse gastric cancer (HDGC) is a relatively rare disorder, with a mutated CDH1 gene as the only known cause. Carriers of a germline mutation in CDH1 have a lifetime risk of >80% of developing diffuse gastric cancer. As periodic gastric surveillance is of limited value in detecting early stages of HDGC, prophylactic gastrectomy is advised for this patient group. Little is known about other types of familial gastric cancer. The Dutch working group on hereditary gastric cancer has formulated guidelines for various aspects of medical management for families and individuals at high risk of developing gastric cancer, including criteria for referral, classification, diagnostics, and periodic gastric surveillance. These guidelines are not limited to HDGC and are therefore partially complementary to the guidelines on hereditary diffuse gastric cancer of the international gastric cancer linkage consortium (IGCLC 2010). In order to optimize the care and increase the knowledge on hereditary gastric cancer it is important to centralize medical care for these patients. National and international collaboration is warranted to improve the quality of research by increasing the size of study cohorts.

PubMed Disclaimer

References

    1. Int J Cancer. 2012 Jul 15;131(2):367-76 - PubMed
    1. Am J Clin Oncol. 2011 Jun;34(3):332-6 - PubMed
    1. Br J Cancer. 2002 Oct 7;87(8):888-91 - PubMed
    1. Lancet Oncol. 2010 May;11(5):439-49 - PubMed
    1. Int J Cancer. 2004 Jan 1;108(1):109-14 - PubMed

Publication types

LinkOut - more resources